We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01283958
Recruitment Status : Completed
First Posted : January 26, 2011
Last Update Posted : January 26, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Condition or disease
Eisenmenger's Syndrome

Study Design

Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Study Start Date : September 2007
Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Diseases
Drug Information available for: Iloprost
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
12 patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization
Criteria

Inclusion Criteria:

  • patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria:

More Information

Responsible Party: Song I Yang, Gil Hospital, Gachon University of Medicine
ClinicalTrials.gov Identifier: NCT01283958     History of Changes
Other Study ID Numbers: no sponsor
First Posted: January 26, 2011    Key Record Dates
Last Update Posted: January 26, 2011
Last Verified: May 2010

Keywords provided by Gachon University Gil Medical Center:
Iloprost, Eisenmenger's syndrome

Additional relevant MeSH terms:
Syndrome
Heart Diseases
Heart Defects, Congenital
Eisenmenger Complex
Disease
Pathologic Processes
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities
Iloprost
Platelet Aggregation Inhibitors
Vasodilator Agents